- Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines for significant unmet medical needs, with two approved products in the U.S. and a strong revenue growth trajectory.
- In 2025, Ardelyx reported approximately $378 million in product revenue, with IBSRELA achieving $274 million, a 73% increase from 2024, and plans to expand its market presence internationally.
- The company has launched a Phase 3 program for IBSRELA in chronic idiopathic constipation and is developing a next-generation NHE3 inhibitor, RDX10531, while maintaining strong patient access strategies for its existing products.
- Ardelyx's ideal buyers include healthcare providers and payers seeking effective treatments for gastrointestinal disorders, as the company addresses significant patient needs and is positioned for continued growth with projected IBSRELA revenues reaching $1 billion by 2029.
Sales and Support is the largest function with 171 employees, accounting for roughly half of the organization. Mid-sized groups include Business Management (30), Engineering (26), Healthcare (24), and Marketing and Product (22). Finance and Administration (19), Operations (13), Human Resources (11), Legal (9), and Other (18) round out the structure. Overall, the company reports 57 hires and 10 departures, with teams spanning go-to-market, technical, healthcare, and administrative roles.
Ardelyx’s workforce is widely distributed, with 226 employees categorized in Other locations (about 66%). The largest city hubs are San Francisco, CA (35) and Boston, MA (33), followed by New York, NY (12), Philadelphia, PA (10), and Los Angeles, CA (9). Additional teams are based in Milwaukee, WI (6), Chicago, IL (5), Dallas, TX (4), and Denver, CO (3). The distribution reflects a primarily dispersed U.S. presence with several concentrated hubs.
